These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179 [TBL] [Abstract][Full Text] [Related]
5. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186 [TBL] [Abstract][Full Text] [Related]
6. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease. Doggrell SA Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903 [No Abstract] [Full Text] [Related]
7. Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy. Sergott RC; Raji A; Kost J; Sur C; Jackson S; Locco A; Patel A; Furtek C; Mattson B; Egan MF J Alzheimers Dis; 2021; 79(1):275-287. PubMed ID: 33252075 [TBL] [Abstract][Full Text] [Related]
8. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606 [TBL] [Abstract][Full Text] [Related]
9. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients. Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025 [TBL] [Abstract][Full Text] [Related]
10. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Li R; Lindholm K; Yang LB; Yue X; Citron M; Yan R; Beach T; Sue L; Sabbagh M; Cai H; Wong P; Price D; Shen Y Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3632-7. PubMed ID: 14978286 [TBL] [Abstract][Full Text] [Related]
11. Merck ends trial of potential Alzheimer's drug verubecestat. Hawkes N BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490 [No Abstract] [Full Text] [Related]
12. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease. Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139 [TBL] [Abstract][Full Text] [Related]
13. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain. Takahashi RH; Tobiume M; Sato Y; Sata T; Gouras GK; Takahashi H Neuropathology; 2011 Jun; 31(3):208-14. PubMed ID: 21062360 [TBL] [Abstract][Full Text] [Related]
14. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285 [TBL] [Abstract][Full Text] [Related]
15. Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model. Meilandt WJ; Ngu H; Gogineni A; Lalehzadeh G; Lee SH; Srinivasan K; Imperio J; Wu T; Weber M; Kruse AJ; Stark KL; Chan P; Kwong M; Modrusan Z; Friedman BA; Elstrott J; Foreman O; Easton A; Sheng M; Hansen DV J Neurosci; 2020 Feb; 40(9):1956-1974. PubMed ID: 31980586 [No Abstract] [Full Text] [Related]
17. Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease. Qu L; Ji L; Wang C; Luo H; Li S; Peng W; Yin F; Lu D; Liu X; Kong L; Wang X Eur J Med Chem; 2021 Jul; 219():113441. PubMed ID: 33862517 [TBL] [Abstract][Full Text] [Related]
18. Maysin and Its Flavonoid Derivative from Centipedegrass Attenuates Amyloid Plaques by Inducting Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg (APPswe, PS1dE9) Alzheimer's Mouse Model. PLoS One; ; . PubMed ID: 28072821 [TBL] [Abstract][Full Text] [Related]